Product Information
RISPERIDONE ER 25 MG VIAL is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $355.2316 per EA under NDC 70748027013. Its NADAC has been published 39 times since Jan 7, 2026.
FDA first approved this application on Sep 2, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Lupin Pharmaceuticals Inc.NDC
70748027013
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA211220FDA Approved
9/2/2025
TE Code
AB
On Market Since
10/17/2025
Price Statistics
The NADAC for RISPERIDONE ER 25 MG VIAL has been published 39 times since Jan 7, 2026, and over the history we have for it it has declined 27.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $355.2316 per EA |
|---|---|
| All-time high | $490.5793 (Jan 14, 2026) |
| All-time low | $350.4721 (Jul 22, 2026) |
| 52-week high | $490.5793 |
| 52-week low | $350.4721 |
| Median price | $415.3331 |
| Average price | $424.8035 |
| Largest weekly change | -11.0% (Jun 17, 2026) |
| Weeks tracked | 39 |
| Tracking since | Jan 7, 2026 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
risperidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RISPERIDONE ER 25 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RISPERIDONE ER 25 MG VIAL, manufactured by Lupin Pharmaceuticals Inc., is $355.2316 per EA (NDC 70748027013), effective Sep 30, 2026.
How has the price of RISPERIDONE ER 25 MG VIAL changed over time?
Over the history we have for it, the NADAC for RISPERIDONE ER 25 MG VIAL has declined 27.6%. It has been tracked across 39 weekly CMS publications since Jan 7, 2026.
What are the highest and lowest recorded NADAC prices for RISPERIDONE ER 25 MG VIAL?
Since Jan 7, 2026, the NADAC for RISPERIDONE ER 25 MG VIAL has ranged from a low of $350.4721 (Jul 22, 2026) to a high of $490.5793 (Jan 14, 2026), with a median of $415.3331 per EA.
Are there cheaper alternatives to RISPERIDONE ER 25 MG VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISPERDAL CONSTA 12.5 MG VIAL, is $317.9314 per EA — about 11% below RISPERIDONE ER 25 MG VIAL.
Who manufactures RISPERIDONE ER 25 MG VIAL?
RISPERIDONE ER 25 MG VIAL (NDC 70748027013) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.